Samsung Valsartan Tablets 160 mg
Valsartan 160mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.
MFDS item code 201904771 · Approved 2019.07.16
This product's status changed to Expired on 2024.07.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension and heart failure, and reduction in the risk of death after myocardial infarction
This medication is used to effectively control blood pressure in patients with essential hypertension. It is also beneficial for heart failure patients with intolerance to ACE inhibitors, particularly those classified as NYHA stages II to IV. Additionally, it is employed to reduce the mortality risk in patients with left ventricular dysfunction following myocardial infarction. Thus, it is useful in treating essential hypertension, heart failure, and post-myocardial infarction, improving the patient's condition.
1. Essential hypertension Take with water during or between meals. It is recommended that you take this medicine at the same time each day (e.g., in the morning), if possible. 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: For patients who are volume depleted (e.g., patients taking high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily, and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with ACE inhibitors is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary if creatinine clearance is 10 mL/min or greater. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be taken by specific patients, including those allergic to the drug or its ingredients, pregnant or nursing women, those with severe liver disease or biliary problems, hereditary angioedema patients, those with severe kidney dysfunction, certain endocrine diseases, and diabetic patients with poor kidney function. Caution is needed for elderly patients or those with high potassium levels, slightly reduced liver function, heart valve disease, hypertrophic cardiomyopathy, cardiovascular disease, or those who are fluid-depleted or sodium-deficient. This medication may cause a rapid drop in blood pressure upon initial use, potentially leading to dizziness or fainting; thus, patients on dialysis or diuretics should start with a low dose while monitoring closely. Regular blood tests to check kidney function and potassium levels are important while taking this medication. This medication may interact with other antihypertensives, particularly potassium-sparing diuretics or potassium supplements, which may lead to dangerously high potassium levels. This medication is not recommended for nursing women, and it is preferable to discontinue breastfeeding while on it. In case of overdose, symptoms like severe hypotension, decreased consciousness, or shock may occur, requiring immediate medical attention. This medication is not recommended for use in children and adolescents, as its safety and efficacy have not been established. Finally, this medication should be kept out of reach of children, and transferring it to other containers is not advisable for quality preservation.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it is important to keep it in a cool place below 30 degrees Celsius to maintain its effectiveness.
Oval film-coated tablet in orange with a gray tint
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan 160mg
Tablet · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.